drugset / Trial / NCT03939182
Abexinostat and Ibrutinib in Diffuse Large B-cell Lymphoma and Mantle Cell Lymphoma
Phase 1
Completed
15 enrolled
Memorial Sloan Kettering Cancer Center
Janssen Scientific Affairs, LLC · collabXynomic Pharmaceuticals, Inc. · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to test the safety of abexinostat at different doses to find out if it can work with ibrutinib to stop the cancer from growing.
Timeline
- Start
- 2019-05-29
- Primary completion
- 2025-04-22
- Completion
- 2025-04-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abexinostat | Small molecule | 30 mg/m2 | Oral |
| Subject | Abexinostat | Small molecule | 45 mg/m2 | Oral |
| Subject | Ibrutinib | Small molecule | 560 mg | Oral |